Use of anagrelide for treating cancer

A compound, wherein the compound is anagrelide, a pharmaceutically acceptable salt, solvate or active metabolite thereof, for use in inhibiting the migratory attraction between circulating cancer cells and bone marrow megakaryocytes.

A compound, wherein the compound is anagrelide, a pharmaceutically acceptable salt, solvate or active metabolite thereof, for use in inhibiting the stimulatory effect of cancer cells on the process of megakaryocytopoiesis and platelet formation in a patient.

The compound for use of any preceding claim, wherein the patient is a thrombocytotic individual at risk of developing cancer

The compound for use of any preceding claim, wherein the patient being treated is a thrombocytotic individual.

The compound for use of any preceding claim, wherein the cancer to be treated is selected from the group consisting of brain, oral cavity, the head and neck (e.g. the nasopharanygeal region), thyroid carcinoma, gastrointestinal cancers (e.g. oesophageal or gastric cancers), pancreatic, hepatocellular cancer, colorectal cancer, cancer of the lungs and bronchus, cancer of the ovaries, endometrium, cervix, breast, prostate, kidneys, skin mesothelioma, melanoma, gallbladder and multiple myeloma.

The compound for use of any preceding claim, formulated as a cardio-sparing/side effect reducing formulation selected from the group consisting of:

• sublingual tablets, buccal spray, mucoadhesive buccal tablets, mucoadhesive buccal films, buccal lozenges/lollipops, rectal suppositories, rectal gels, nasal spray, pulmonary delivery devices, transdermal patches gels ointments or creams, injectable formulations including those given intravenously, intramuscularly or subcutaneously as immediate and sustained release preparations.

The compound for use of any preceding claim, wherein the platelet count is reduced to an upper limit of 400×103/μL but above a lower limit of 150×103/μL.

The compound for use of any preceding claim, wherein the platelet count is reduced to an upper limit of 350×103/μL but above a lower limit of 150×103/μL.

The compound for use of any preceding claim, wherein the platelet count is reduced to an upper limit of 300×103/μL but above a lower limit of 150×103/μL

The compound for use of any preceding claim, wherein the platelet count is reduced to an upper limit of 250×103/μL but above a lower limit of 150×103/μL